| Annual Financials | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Revenue  | 0 | 887 | 1,549 | 1,886 | 2,138 | 2,190 | 2,295 | 2,387 |
| Expenses | 0 | 639 | 1,065 | 1,294 | 1,507 | 1,519 | 1,609 | 1,704 |
| EBITDA | 0 | 248 | 484 | 592 | 631 | 671 | 686 | 683 |
| Operating Profit % | -5 % | 28 % | 31 % | 31 % | 29 % | 30 % | 30 % | 29 % |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 54 | 61 |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 |
| Profit Before Tax | 0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 |
| Tax | 0 | 33 | 108 | 119 | 146 | 162 | 160 | 162 |
| Net Profit | -0 | 196 | 313 | 352 | 419 | 467 | 471 | 492 |
| EPS in ₹ | -7.89 | 24.64 | 29.04 | 32.61 | 35.63 | 38.11 | 38.43 | 39.63 |
Alivus Life Sciences
Alivus Life Sciences
1,028.40
+5.40
(0.53%)
Market Cap
12,545.00 Cr
EPS
39.63
PE Ratio
25.84
Dividend Yield
0.49 %
Industry
Healthcare52 Week High
1,251.00
52 Week Low
850.00
PB Ratio
4.45
Debt to Equity
0.01
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
Company News
View All News
Alivus Life Sciences Receives USFDA No Action Indicated Classification for Gujarat API Facility
Today
TodayAlivus Life Sciences Limited received an Establishment Inspection Report with a No Action Indicated (NAI) classification from the USFDA for its API manufacturing facility located in Dahej, Gujarat. The classification follows a USFDA inspection conducted from May 26 to May 30, 2025. The NAI classification indicates that the facility met regulatory standards during the inspection. The company was formerly known as Glenmark Life Sciences Limited.
Alivus Life Sciences Schedules Q1 FY2025-26 Earnings Call for August 2, 20251 day ago
Alivus Life Sciences Limited has scheduled an earnings call to discuss its Q1 FY2025-26 financial performance on Saturday, August 2, 2025, from 8:30 AM to 9:30 AM IST. The company has provided multiple dial-in numbers for participants, including universal dial-in numbers for India and international toll-free and toll numbers for various countries including Australia, Canada, China, Hong Kong, Italy, Japan, Singapore, South Korea, UK, and USA. The company was formerly known as Glenmark Life Sciences Limited. Contact persons for clarifications are Diwakar Pingle and Runjhun Jain from EY.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,699.00 | #1 4,05,967.50 | 35.44 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 54.94 | |
6,616.50 | 1,75,700.40 | 80.22 | 9,712.00 | 0.89 | 2,191 | 23.05 | 42.61 | |
1,532.50 | 1,20,178.80 | 23.35 | 28,409.50 | 7.12 | 5,291 | 9.88 | 63.13 | |
3,603.80 | 1,19,129.40 | 62.12 | 11,539.40 | 11.59 | 1,911 | 10.91 | 71.36 | |
2,603.40 | 1,06,876.10 | 61.51 | 12,744.20 | 19.57 | 2,007 | -10.91 | 60.17 | |
1,277.90 | 1,05,615.00 | #1 18.58 | 33,741.20 | 16.73 | 5,725 | 1.26 | 51.48 | |
976.40 | 97,730.50 | 21.02 | 23,511.00 | 13.82 | 4,615 | -0.19 | 53.23 | |
1,951.00 | 88,662.90 | 27.33 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 51.88 | |
33,780.00 | 73,480.10 | 52.02 | 6,684.70 | 10.80 | 1,414 | 27.83 | 50.65 | |
1,122.80 | 64,707.10 | 18.71 | 31,378.10 | 17.55 | 3,366 | -0.50 | 45.80 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
4.80 %
Net Income Growth
0.84 %
Cash Flow Change
35.13 %
ROE
-7.55 %
ROCE
-8.03 %
EBITDA Margin (Avg.)
-2.45 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 |
| Fixed Assets | 0 | 456 | 546 | 573 | 590 | 781 | 805 | 1,057 |
| Current Assets | 0 | 931 | 1,160 | 1,399 | 1,765 | 1,850 | 1,916 | 2,335 |
| Capital Work in Progress | 0 | 80 | 11 | 14 | 97 | 62 | 106 | 94 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 674 |
| Other Assets | 0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | 0 |
| Total Liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 |
| Current Liabilities | 2 | 1,380 | 1,308 | 1,221 | 384 | 497 | 439 | 470 |
| Non Current Liabilities | 0 | 7 | 16 | 23 | 33 | 67 | 79 | 124 |
| Total Equity | -1 | 88 | 402 | 753 | 2,054 | 2,138 | 2,332 | 2,817 |
| Reserve & Surplus | -1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 | 2,793 |
| Share Capital | 0 | 2 | 2 | 2 | 25 | 25 | 25 | 25 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 |
| Investing Activities | 0 | -9 | -51 | -69 | -122 | -147 | -117 |
| Operating Activities | -1 | 10 | 195 | 388 | 598 | 306 | 414 |
| Financing Activities | 1 | 1 | -137 | -214 | -79 | -388 | -279 |
Share Holding
| % Holding | Apr 2021 | Aug 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 100.00 % | 82.84 % | 82.84 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 75.00 % | 75.00 % | 74.99 % | 74.94 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 4.38 % | 0.00 % | 5.01 % | 4.82 % | 7.85 % | 6.74 % | 6.57 % | 6.42 % |
| DIIs | 0.00 % | 1.34 % | 0.30 % | 0.32 % | 0.50 % | 0.71 % | 0.79 % | 0.09 % | 0.00 % | 0.58 % | 0.64 % | 0.59 % | 1.40 % | 1.57 % | 4.16 % | 4.86 % | 5.19 % | 5.61 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 7.99 % | 7.97 % | 7.72 % | 7.80 % | 8.14 % | 9.14 % | 9.77 % | 10.87 % | 10.02 % | 9.20 % | 9.20 % | 9.09 % | 9.13 % | 10.63 % | 10.99 % | 10.50 % | 10.34 % |
| Others | 0.00 % | 7.83 % | 8.89 % | 9.11 % | 8.86 % | 8.31 % | 7.21 % | 7.29 % | 6.28 % | 6.55 % | 2.92 % | 7.36 % | 1.64 % | 1.64 % | 2.36 % | 2.41 % | 2.74 % | 2.69 % |
| No of Share Holders | 7 | 3,73,362 | 2,80,300 | 2,53,726 | 2,38,578 | 2,33,538 | 2,32,203 | 2,25,730 | 2,22,866 | 2,08,267 | 1,98,764 | 1,85,531 | 1,56,183 | 1,49,396 | 1,43,960 | 1,46,840 | 1,41,977 | 1,38,500 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21 | 42 | 22.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.49 | 5.41 | 2.08 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 15 May 2025 |  Quarterly Result Announcement | NA | 15 May 2025 | 1,110.95 | 1,180.60 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 1,065.60 | 1,122.65 |
| 24 Oct 2024 | Quarterly Result Announcement | NA | 24 Oct 2024 | 1,173.20 | 1,073.35 |
| 09 Oct 2024 |  Change Of Name | NA | 09 Oct 2024 | 1,203.25 | 1,203.25 |
| 25 Sept 2024 |  Annual General Meeting | NA | 25 Sept 2024 | 1,076.05 | 1,107.00 |
| 17 Oct 2023 |  Dividend | ₹ 22.50 /share | 17 Oct 2023 | 624.60 | 667.90 |
| 24 Mar 2023 | Dividend | ₹ 21.00 /share | 24 Mar 2023 | 382.65 | 413.10 |
| 17 Sept 2022 | Dividend | ₹ 10.50 /share | 15 Sept 2022 | 489.00 | 418.95 |
| 23 Nov 2021 | Dividend | ₹ 10.50 /share | 22 Nov 2021 | 637.10 | 611.65 |
Announcements
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 201528 minutes ago
28 minutes ago Shareholder Meeting / Postal Ballot-Scrutinizer"s Report1 day ago
1 day agoShareholder Meeting / Postal Ballot-Outcome of Postal_Ballot1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
1 day agoClosure of Trading Window1 day ago
1 day agoBoard Meeting Intimation for Inter Alia To Consider And Approve The Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2025.2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationJun 24, 2025
Jun 24, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
May 30, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
May 15, 2025Appointment Of Secretarial AuditorMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 15, 2025
May 15, 2025Corporate Action-Board to consider DividendMay 15, 2025
May 15, 2025Board Meeting Outcome for Audited Financial Results For The Fourth Quarter And Year Ended March 31 2025May 15, 2025
May 15, 2025Audited Financial Results For The Fourth Quarter And Year Ended March 31 2025May 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
May 08, 2025Closure of Trading WindowMay 08, 2025
May 08, 2025Board Meeting Intimation for To Consider And Approve The Audited Financial Results Of The Company For The Quarter And Year Ended 31St March 2025 And To Consider And Recommend Dividend If Any On Equity Shares For The Year Ended March 31 2025.May 08, 2025
May 08, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 30, 2025
Apr 30, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 17, 2025
Apr 17, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 03, 2025
Apr 03, 2025Announcement under Regulation 30 (LODR)-AcquisitionApr 02, 2025
Apr 02, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 07, 2025
Mar 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 27, 2025
Feb 27, 2025Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 26, 2025
Feb 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 21, 2025
Feb 21, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 31, 2025
Jan 31, 2025Transcript Of Earnings Call.Jan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 23, 2025
Jan 23, 2025Integrated Filing (Financial)Jan 23, 2025
Jan 23, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 23, 2025
Jan 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 23, 2025
Jan 23, 2025Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31 2024Jan 23, 2025
Jan 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 18, 2025
Jan 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 17, 2025
Jan 17, 2025Closure of Trading WindowJan 16, 2025
Jan 16, 2025Board Meeting Intimation for Inter Alia To Consider And Approve The Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended 31St December 2024Jan 16, 2025
Jan 16, 2025Announcement under Regulation 30 (LODR)-Change of Company NameDec 17, 2024
Dec 17, 2024Shareholder Meeting / Postal Ballot-Scrutinizers ReportNov 27, 2024
Nov 27, 2024Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotNov 27, 2024
Nov 27, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 25, 2024
Nov 25, 2024Technical Indicators
RSI(14)
Neutral 48.62
ATR(14)
Less Volatile 31.38
STOCH(9,6)
Neutral 36.96
STOCH RSI(14)
Neutral 22.50
MACD(12,26)
Bullish 0.11
ADX(14)
Weak Trend 18.39
UO(9)
Bearish 37.91
ROC(12)
Uptrend And Accelerating 1.65
WillR(14)
Neutral -71.65
Mutual Fund Holdings
Tata Small Cap Fund Direct - Growth 
Union Multicap Fund Direct - Growth 
Old Bridge Focused Fund Direct - Growth 
Motilal Oswal Quant Fund Direct-Growth 
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth 
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
